分子靶向药物酪氨酸激酶抑制剂的心脏毒性研究进展  

Research progress on cardiotoxicity of tyrosine kinase inhibitors(molecular targeting drug)

作　　者：盖仁华[1] 赵玉勤[2] 平丽[1] 吴洪海[1] 何俏军[1] 

机构地区：[1]浙江大学药物安全评价研究中心,浙江杭州310058 [2]浙江海洋学院,浙江舟山316000

出　　处：《中国医药导报》2012年第31期37-38,41,共3页China Medical Herald

基　　金：国家自然科学基金(项目编号:81001478)

摘　　要：蛋白酪氨酸激酶(protein tyrosine kinases,PTKs)通路在肿瘤细胞的增殖、修复、转移及新生血管生成等方面起着非常重要的作用。鉴于靶向治疗在临床应用中取得的显著效果,已成为肿瘤治疗的新热点。然而,尽管酪氨酸激酶抑制剂的靶向治疗专一性很强,也常常出现心血管不良反应。本文对根据不同的酪氨酸激酶抑制剂所产生的心脏毒性及其机制进行综述。Protein tyrosine kinases（PTKs） pathway plays an important role in tumor cell proliferation,wound healing,invasion and neovascular formation.Targeting PTKs drug achieved very encouraging results in clinical applications,has become the new hot spot of tumor treatment.However,even highly specific tumor molecular targeted therapy,also tend to appear cardiovascular adverse reactions.Cardiac toxicity according to the different pathways of the role of tumor molecular targeted drugs and their mechanisms are reviewed in this paper.

关 键 词：靶向药物 酪氨酸激酶抑制剂 心脏毒性 

分 类 号：R979.1[医药卫生—药品]